Press Releases

HHS Enlists Archimedes Inc. To Expand Government’s Use Of Health Care Modeling For Forecasting Quality And Cost Outcomes

San Francisco CA and Princeton NJ – May 3, 2012 – To put high-powered mathematical analytics in the hands of its agencies, the U.S. Department of Health and Human Services (HHS) has contracted with Archimedes Inc., a healthcare modeling company based in San Francisco CA. The contract will put the Archimedes model at the fingertips of its agencies, enabling them to research, analyze, and evaluate the effects of specific health care interventions more quickly and accurately. More...

Quintiles To Quantify Healthcare Decisions Using Archimedes Simulator

San Francisco, CA and Research Triangle Park, NC – March 28, 2012 – Quintiles and Archimedes Inc. today announced an agreement to co-promote clinical and commercial solutions for biopharmaceutical companies to help reduce the time and expense associated with developing and marketing novel therapies. Through this partnership, Quintiles will incorporate Archimedes’ industry-leading healthcare modeling technology, the ARCHeS Innovator, and expertise into its existing solutions that span the product lifecycle. More...

Archimedes’ Individualized Guidelines and Outcomes (IndiGO) Deployed at Tulsa Health System

San Francisco, CA and Tulsa, OK – January 19, 2012 – Archimedes Inc., a healthcare modeling company, and MyHealth Access Network, a Beacon Community in Oklahoma, today announced the planned deployment of Archimedes’ Individualized Guidelines and Outcomes (IndiGO) platform, a physician and patient decision support tool.  IndiGO could ultimately be used by doctors to work with their patients to inform the health decisions of as many as 810,000 Oklahomans.  The MyHealth Access Network deployment marks the third deployment of the tool in the past three months. More...

Archimedes’ Individualized Guidelines and Outcomes (IndiGO) Platform Deployed in Colorado Beacon Consortium

San Francisco, CA – December 7, 2011 – Archimedes Inc., a healthcare modeling company, today announced that it has entered into an agreement with the Colorado Beacon Consortium (CBC) for the use of the Company’s Individualized Guidelines and Outcomes (IndiGO) platform, a physician and patient decision support tool.  Initially, IndiGO will be used as part of a one-year program throughout the CBC’s medical practices to assist in the care of up to 100,000 patients. More...

Archimedes, Inc. Partners with Minnesota Health System to Deploy Individualized Guidelines and Outcomes (IndiGO) Platform

San Francisco, CA – November 17, 2011 – Archimedes Inc., a healthcare modeling company, today announced that it has entered into an agreement with Minnesota’s Fairview Health Services for the use of Archimedes’ Individualized Guidelines and Outcomes (IndiGO) platform, a physician and patient decision support tool. More....

Archimedes, Inc. Improves Accessibility Of Healthcare Simulation Model Through Launch of ARCHeS Innovator

San Francisco, CA – May 23, 2011 – Archimedes Inc., a healthcare modeling company, today announced the launch of a new web interface, ARCHeS Innovator, which will give health experts direct access to many of the features of the Archimedes Model. More...

Archimedes Partners with Novo Nordisk to Evaluate the Effects of Health Checks in Europe

San Francisco, CA - March 24, 2011 Archimedes Inc., a healthcare modeling company, today announced a collaboration with Novo Nordisk A/S, a world leader in diabetes care, to evaluate the effects of standardized vascular health checks on expected health outcomes. Archimedes will simulate these effects in a variety of European populations using the Archimedes Model. More...

Archimedes, Inc. and FDA Announce Collaboration to Evaluate the Clinical Risks and Benefits of Weight Loss Medications

San Francisco, CA - January 20, 2011 — Archimedes Inc., a healthcare modeling company, announced today that it has entered into a Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA) to develop a computer model of clinical trials evaluating weight loss medications. The model will be used to obtain a better understanding of the benefits of weight loss against the long-term risks of cardiovascular outcomes in patients treated with weight loss drugs. More...